Can I Take Zinc with Vyleesi (Bremelanotide)?

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women [1]. It binds melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system, modulating dopaminergic and noradrenergic pathways that mediate sexual desire [2].

The drug is delivered as a 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity. Patients use it no more than once per 24-hour period and no more than about eight times per month per prescribing guidance [1].

Metabolism and Excretion

Bremelanotide is metabolized through proteolytic cleavage, not through hepatic cytochrome P450 enzymes [1]. That single pharmacokinetic fact is important: most common supplement-drug interactions occur through CYP3A4, CYP2D6, or other CYP isoforms. Zinc does not meaningfully inhibit or induce those same enzymes either, which is one reason the combination raises no pharmacokinetic red flags in the FDA's interaction database [3].

Renal elimination accounts for a significant portion of bremelanotide clearance. Peak plasma concentration (Cmax) is reached at approximately 1 hour post-injection, and the mean terminal half-life is roughly 2.7 hours [1].

What the RECONNECT Trials Showed

The RECONNECT phase 3 program enrolled 1,247 premenopausal women with HSDD across two randomized, double-blind, placebo-controlled trials [4]. At 24 weeks, more women receiving bremelanotide reported a meaningful increase in desire scores (as measured by the Female Sexual Function Index desire domain) compared with placebo, with statistically significant improvement (P<0.001) [4]. Distress scores, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm, also improved significantly. Neither trial tracked concomitant supplement use in a way that permits subgroup analysis.

What Does Zinc Do in the Body?

Zinc is an essential trace mineral involved in more than 300 enzymatic reactions [5]. For sexual health specifically, its roles touch testosterone synthesis, thyroid hormone metabolism, and antioxidant defense.

Zinc and Testosterone

Zinc functions as a cofactor for 17-beta-hydroxysteroid dehydrogenase, an enzyme involved in converting androstenedione to testosterone [6]. In men with marginal zinc deficiency, supplementation at 25 mg/day for six months raised serum testosterone significantly in one small controlled trial [6]. Evidence in premenopausal women is more limited; a 2021 review in the Journal of Trace Elements in Medicine and Biology noted that female androgen production is far less zinc-dependent than male gonadal function, and no large trial has confirmed a libido-specific zinc benefit in women with normal zinc status [7].

The practical implication: a woman with documented zinc deficiency might have mildly suppressed androgen activity, but correcting that deficiency with standard supplementation (8 to 25 mg/day) is unlikely to produce a pharmacodynamic clash with a centrally acting peptide like bremelanotide.

Zinc-Copper Balance

High-dose zinc is the most clinically significant zinc interaction concern in general medicine [8]. Zinc competes with copper for intestinal absorption via metallothionein induction. The FDA-approved label for zinc acetate (used in Wilson disease) explicitly notes that doses above 40 mg/day over months can deplete copper [9]. Copper deficiency causes anemia, neuropathy, and disrupted cytochrome c oxidase activity.

From a hormonal standpoint, copper is a cofactor for dopamine beta-hydroxylase, which converts dopamine to norepinephrine [10]. Dopamine is the neurotransmitter most directly tied to desire signaling, and it is the same pathway bremelanotide modulates centrally. Severe copper depletion caused by prolonged high-dose zinc could theoretically blunt dopaminergic tone, which might reduce bremelanotide's downstream effect. This is a pharmacodynamic hypothesis, not a documented clinical finding.

Does Zinc Interact with Vyleesi Pharmacokinetically?

No. The FDA prescribing information for Vyleesi does not list zinc or any mineral supplement as a drug interaction [1]. Bremelanotide's proteolytic clearance pathway is entirely separate from the transport proteins and metabolic enzymes through which zinc exerts its limited drug-interaction effects [3].

Absorption-Level Interactions

Some minerals, notably calcium, magnesium, and iron, bind to certain drugs in the gastrointestinal tract and reduce absorption. Bremelanotide bypasses the GI tract entirely because it is given subcutaneously [1]. Oral zinc cannot interfere with the absorption of an injected peptide.

Protein Binding and Renal Clearance

Bremelanotide plasma protein binding is approximately 21% [1]. Zinc does not compete for the same albumin or alpha-2-macroglobulin binding sites that bremelanotide uses. Renal clearance of the peptide is also unaffected by zinc because zinc is handled by separate transporters (ZIP and ZnT families) in the proximal tubule [11].

Pharmacodynamic Considerations: Where the Theoretical Overlap Lives

Even without a pharmacokinetic interaction, two substances can interfere when they affect the same physiological pathway in opposite directions. Here is where the zinc-bremelanotide picture gets more nuanced.

Central Dopamine Pathway

Bremelanotide activates MC4R in the paraventricular nucleus of the hypothalamus, which increases dopamine release in limbic circuits associated with sexual arousal [2]. Zinc itself modulates N-methyl-D-aspartate (NMDA) receptor activity and can inhibit certain dopamine transporter functions at high concentrations in vitro [12]. Whether oral zinc at physiologic doses (8 to 40 mg/day) produces brain zinc levels high enough to affect dopamine transporter activity meaningfully in humans is not established. A 2020 study in Nutritional Neuroscience found that dietary zinc intake correlated with dopamine turnover markers in rodent models, but human translation remains speculative [13].

Melanocortin Receptor Modulation

Zinc ions can act as allosteric modulators of GPCRs, including some melanocortin receptors, in cell-line studies [14]. At physiologic concentrations, this effect is minimal. No human pharmacology study has examined whether oral zinc supplementation changes MC4R sensitivity or bremelanotide's receptor occupancy in vivo.

A Practical Risk-Stratification Framework

Based on the available evidence, clinicians can categorize patients taking both zinc and bremelanotide into three tiers:

Tier 1 (Low concern): Zinc at or below the RDA (8 mg/day from food and supplements combined). No interaction monitoring beyond routine care. Continue as prescribed.

Tier 2 (Moderate watchfulness): Zinc 9 to 40 mg/day from supplements. Remains within the tolerable upper intake level established by the Institute of Medicine [8]. Verify no frank copper deficiency at baseline. Reassess copper and ceruloplasmin at 6 months if supplementation is ongoing.

Tier 3 (Clinician review warranted): Zinc above 40 mg/day or any therapeutic zinc formulation. Discuss risk-benefit with prescribing physician before combining with bremelanotide. Serum copper, ceruloplasmin, and CBC to screen for copper-deficiency anemia should be obtained at baseline and at 3 months.

What the Guidelines Say About Zinc Safety

The Institute of Medicine set the tolerable upper intake level (UL) for zinc at 40 mg/day for adult women, based on studies of copper metabolism [8]. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not mention zinc supplementation as an adjunct or a concern in the context of pharmacotherapy [15].

The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that no dietary supplement has demonstrated efficacy for HSDD equivalent to approved pharmacotherapy, and recommends against replacing proven agents with unproven supplements [16]. That guidance does not prohibit combining supplements with Vyleesi; it simply cautions against substitution.

As the Endocrine Society guideline states directly: "Clinicians should encourage patients to disclose all dietary supplements and herbal products because of potential interactions with prescribed medications, even when interaction data are limited." [15]

Zinc Deficiency and HSDD: Is There a Connection?

Zinc deficiency is more common than many clinicians recognize. The National Health and Nutrition Examination Survey (NHANES) data suggest that approximately 12% of U.S. Women consume less than the estimated average requirement for zinc [17]. Symptoms of deficiency overlap with general fatigue and mood disturbance, both of which can reduce sexual desire independent of any HSDD diagnosis.

A 2016 cross-sectional analysis published in the Archives of Gynecology and Obstetrics (N=116 premenopausal women) found that women with lower serum zinc levels reported higher Female Sexual Distress Scale scores, suggesting an association between zinc status and sexual distress [18]. Associations are not causation, and this single study does not support routine zinc supplementation for HSDD. Still, screening zinc status in a woman presenting with HSDD is reasonable clinical practice, particularly if her diet is low in animal protein or she has a condition associated with malabsorption.

When to Test Zinc Status

Testing is reasonable before starting any zinc supplement over 15 mg/day. Serum zinc is an imperfect marker because it does not fully reflect total body stores, but a fasting morning level below 70 mcg/dL in a woman with dietary risk factors is actionable [5]. Plasma zinc measured in the morning before eating is more reliable than random-draw serum zinc.

Nausea: A Shared Side Effect to Watch

Nausea is the most common adverse effect of bremelanotide. In the RECONNECT trials, 40.1% of women using bremelanotide reported nausea compared with 1.5% on placebo [4]. Taking high-dose zinc supplements on an empty stomach also causes nausea in a substantial portion of users, an effect well documented in the supplement literature [5].

Combining both on the same day, particularly if zinc is taken close to the time of bremelanotide injection, may increase nausea severity additively. No trial has quantified this additive risk, but the mechanism is straightforward: bremelanotide's nausea arises from central melanocortin activation, while zinc's nausea arises from gastric irritation. These are different mechanisms, so both can occur simultaneously.

Practical Mitigation

Take zinc supplements with food and not within two hours of the bremelanotide injection. Food does not affect bremelanotide's subcutaneous absorption [1], so there is no clinical downside to this scheduling. Patients who experience severe nausea on bremelanotide alone should report this to their prescriber before adding any supplement that independently causes nausea.

What to Tell Your Prescriber

Full transparency about supplement use matters for safe care. A retrospective analysis of adverse drug reactions at U.S. Hospitals found that supplement-drug interactions contributed to 4% of hospital admissions where interactions were implicated, with mineral supplements accounting for a disproportionate share of those cases [19].

For bremelanotide specifically, relevant disclosures include:

• All zinc-containing supplements, including multivitamins, zinc lozenges, and zinc-fortified protein powders
• Copper supplements, because they directly affect the zinc-copper balance
• Any hormonal treatments, including testosterone therapy, because zinc and androgens share overlapping biosynthetic pathways [6]
• Iron supplements, because high-dose iron can also affect zinc absorption in the gut [5]

Summary of Interaction Status

Zinc at RDA doses does not interact with bremelanotide pharmacokinetically. The proteolytic peptide metabolism of bremelanotide and the mineral transport biology of zinc occupy entirely separate biochemical lanes [1, 3]. The one area requiring clinical attention is high-dose zinc (above 25 to 40 mg/day) and its potential to deplete copper, which could theoretically reduce the dopaminergic substrate that bremelanotide needs to produce its effect [10]. This remains a mechanistic hypothesis without confirmatory human data.

Women using Vyleesi who want to take zinc for documented deficiency, immune support, or skin health should take zinc at or below 40 mg/day, tell their prescriber, and take the supplement with food rather than on the day of injection if nausea has been a problem.